SCHEMBL4678617

SCHEMBL4678617

O=C(C=C(O)c1nc[nH]n1)c1nc(Cc2cccc(F)c2)cs1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCAR2 Q8TDS4 3/20 0.38
TP53 P04637 2/20 0.36
KDM4E B2RXH2 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
HDAC1 Q13547 1/20 0.36
HDAC6 Q9UBN7 1/20 0.36
PTGER1 P34995 1/20 0.36
CACNA1G O43497 1/20 0.33
CACNA1H O95180 1/20 0.33
CACNA1I Q9P0X4 1/20 0.33
SNCA P37840 1/20 0.33
MMP1 P03956 1/20 0.33
MMP2 P08253 1/20 0.33
MMP9 P14780 1/20 0.33
MMP13 P45452 1/20 0.33
THRB P10828 1/20 0.33
MAPT P10636 1/20 0.33
NR3C2 P08235 1/20 0.33
NR4A2 P43354 1/20 0.33
GSK3B P49841 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4676888 0.89 PTGER1 (0.39) TP53KDM4ESMN1; SMN2HDAC1HDAC6
SCHEMBL4672331 0.88 LMNA (0.36) TP53SMN1; SMN2HDAC1HDAC6PTGER1
SCHEMBL4679142 0.85 HCAR2 (0.38) HCAR2KDM4ESMN1; SMN2HDAC1HDAC6
SCHEMBL5899404 0.83 PTGER1 (0.32) PTGER1
SCHEMBL4674104 0.83 MMP1 (0.42) HCAR2SMN1; SMN2HDAC1HDAC6PTGER1
SCHEMBL4675277 0.82 PTGER1 (0.37) KDM4ESMN1; SMN2PTGER1
SCHEMBL4676758 0.82 HCAR2 (0.39) HCAR2SNCAMMP1MMP2MMP9
SCHEMBL4671162 0.82 RAB9A (0.32) KDM4ESMN1; SMN2PTGER1CACNA1GCACNA1H
SCHEMBL4675484 0.82 PTGER1 (0.32) HDAC1HDAC6PTGER1
SCHEMBL4678117 0.82 HCAR2 (0.39) HCAR2PTGER1THRBNR3C2NR4A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 HCAR2 276/4885TP53 999/4885KDM4E 947/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.